Mereo BioPharma Group Statistics
Total Valuation
MREO has a market cap or net worth of $362.52 million. The enterprise value is $300.78 million.
Important Dates
The last earnings date was Tuesday, May 13, 2025, before market open.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MREO has 159.00 million shares outstanding. The number of shares has increased by 12.10% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 159.00M |
| Shares Change (YoY) | +12.10% |
| Shares Change (QoQ) | +1.19% |
| Owned by Insiders (%) | 5.00% |
| Owned by Institutions (%) | 50.56% |
| Float | 112.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.03 |
| P/TBV Ratio | 6.09 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.92, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.92 |
| Quick Ratio | 8.65 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -38.15 |
Financial Efficiency
Return on equity (ROE) is -91.70% and return on invested capital (ROIC) is -53.91%.
| Return on Equity (ROE) | -91.70% |
| Return on Assets (ROA) | -47.59% |
| Return on Invested Capital (ROIC) | -53.91% |
| Return on Capital Employed (ROCE) | -77.78% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.31M |
| Employee Count | 36 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.16% in the last 52 weeks. The beta is 0.47, so MREO's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -25.16% |
| 50-Day Moving Average | 2.33 |
| 200-Day Moving Average | 3.36 |
| Relative Strength Index (RSI) | 46.56 |
| Average Volume (20 Days) | 1,076,184 |
Short Selling Information
| Short Interest | 7.61M |
| Short Previous Month | 6.60M |
| Short % of Shares Out | 6.73% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.97 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -47.31M |
| Pretax Income | n/a |
| Net Income | -47.19M |
| EBITDA | -46.73M |
| EBIT | -47.31M |
| Earnings Per Share (EPS) | -$0.31 |
Full Income StatementBalance Sheet
The company has $62.48 million in cash and $747,000 in debt, giving a net cash position of $61.74 million or $0.39 per share.
| Cash & Cash Equivalents | 62.48M |
| Total Debt | 747,000 |
| Net Cash | 61.74M |
| Net Cash Per Share | $0.39 |
| Equity (Book Value) | 60.08M |
| Book Value Per Share | 0.38 |
| Working Capital | 59.40M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$33.17 million and capital expenditures -$20,000, giving a free cash flow of -$33.19 million.
| Operating Cash Flow | -33.17M |
| Capital Expenditures | -20,000 |
| Free Cash Flow | -33.19M |
| FCF Per Share | -$0.21 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |